Budget Agreement Could Doom Proposed Boost in Research

NEWS ANALYSIS WASHINGTON—Budget analysts refer to it as Account 302b. But scientists may want to use more colorful names once they realize it will almost certainly block the sizable R&D increases being proposed for 1989 by President Reagan. The budget process works well when spending is rising gradually each year,” observed John Hoimfeld, a staff member of the House Science, Space and Technology Committee who later this year will complete a multi-volume report on science policy fo

Written byJeffrey Mervis
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

WASHINGTON—Budget analysts refer to it as Account 302b. But scientists may want to use more colorful names once they realize it will almost certainly block the sizable R&D increases being proposed for 1989 by President Reagan.

The budget process works well when spending is rising gradually each year,” observed John Hoimfeld, a staff member of the House Science, Space and Technology Committee who later this year will complete a multi-volume report on science policy for the committee. “But it breaks down when the budget must be flattened out or reduced.”

Last year it fell on the national Science Foundation, which saw an expected 17 percent increase shrink to less than 6 percent after officials had fought for months to persuade House and Senate panels that the extra funds were vital. The factors that gutted their efforts last year promise to do similar damage to this year’s request.

To understand U.S. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies